Cargando…

Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy

SIMPLE SUMMARY: Recent research on prostate cancer and vitamin D is controversial. We measured three vitamin D(3) metabolites in 32 selected prostate cancer patients after surgery at four time points over four years. Within a large European study, half of the patients were prophylactically treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stephan, Carsten, Ralla, Bernhard, Bonn, Florian, Diesner, Max, Lein, Michael, Jung, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946001/ https://www.ncbi.nlm.nih.gov/pubmed/35326710 http://dx.doi.org/10.3390/cancers14061560

Ejemplares similares

Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors
por: Rochow, Hannah, et al.
Publicado: (2020)

Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis
por: Watanabe, Daisuke, et al.
Publicado: (2021)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature
por: Zhao, Zhongwei, et al.
Publicado: (2019)

PHI density prospectively improves prostate cancer detection
por: Stephan, Carsten, et al.
Publicado: (2021)

Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity
por: Stephan, Carsten, et al.
Publicado: (2008)

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Application of Primary/Secondary Circulating Tumor Cells for the Prediction of Biochemical Recurrence in Nonmetastatic Prostate Cancer Patients following Radical Prostatectomy or Radiotherapy: A Meta-Analysis
por: Cao, Liang, et al.
Publicado: (2021)

Early Continence and Extravasation After Open Retropubic Radical Prostatectomy – Interrupted vs Continuous Suturing for Vesicourethral Anastomosis
por: Köhler, Nora, et al.
Publicado: (2020)

Does the Prostate Health Index Depend on Tumor Volume?—A Study on 196 Patients after Radical Prostatectomy
por: Friedersdorff, Frank, et al.
Publicado: (2017)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2023)

Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trial
por: Krause, Sonja, et al.
Publicado: (2012)

Relevance of Biotin Deficiency in Patients with Inflammatory Bowel Disease and Utility of Serum 3 Hydroxyisovaleryl Carnitine as a Practical Everyday Marker
por: Erbach, Johanna, et al.
Publicado: (2022)

Instability of circular RNAs in clinical tissue samples impairs their reliable expression analysis using RT-qPCR: from the myth of their advantage as biomarkers to reality
por: Rochow, Hannah, et al.
Publicado: (2020)

The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients
por: Maxeiner, Andreas, et al.
Publicado: (2017)

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
por: D'Amico, Anthony V., et al.
Publicado: (2021)

Summary of the Standards, Options and Recommendations for the management of patients with nonmetastatic prostate cancer (2001)
por: Villers, A, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
por: López-Campos, Fernando, et al.
Publicado: (2021)

Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
por: Yoshimura, Koji, et al.
Publicado: (2022)

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
por: Rasmussen, Kelli M., et al.
Publicado: (2023)

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
por: Appukkuttan, Sreevalsa, et al.
Publicado: (2021)

Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score
por: Hu, Xin-Hai, et al.
Publicado: (2014)

Circular RNAs in Clear Cell Renal Cell Carcinoma: Their Microarray-Based Identification, Analytical Validation, and Potential Use in a Clinico-Genomic Model to Improve Prognostic Accuracy
por: Franz, Antonia, et al.
Publicado: (2019)

Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2017)

Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model
por: Thurtle, David R., et al.
Publicado: (2019)

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
por: Esgueva, Raquel, et al.
Publicado: (2010)

Association between serum Vitamin D levels and prognostic factors in nonmetastatic breast cancer patients
por: Shahrzad, Mohammad Karim, et al.
Publicado: (2022)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Effects of Marine Phospholipids Extract on the Lipid Levels of Metastatic and Nonmetastatic Prostate Cancer Patients
por: Küllenberg de Gaudry, Daniela, et al.
Publicado: (2014)

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment
por: Srinivas, Sandy, et al.
Publicado: (2020)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gahg7485ev00i6mciu2l3jegff